Ionis Pharmaceuticals | Sustainability & Chart

US4622221004

Basic information on Ionis Pharmaceuticals

Location: United States

Industry: Health Services

Website

Impact Score

Description Ionis Pharmaceuticals

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that specializes in discovering and developing RNA-targeted therapeutics for patients with serious diseases.

Ionis Pharmaceuticals Sustainability Performance

Climate

40%

Renewable Energy

Ionis Pharmaceuticals obtains 45,6% of its energy from renewable energies. Target value per method: min. 100%

Greenhouse Gas Emissions

Ionis Pharmaceuticals emits 95% of its CO₂ budget of 6,041 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Supply Chain

No data available for Ionis Pharmaceuticals. Target value per method: max. 100% of CO₂ budget

Recycling and Recovery of Waste

Ionis Pharmaceuticals recycles 11,6% of its waste. Target value per method: min. 75%

Society

67%

Union Formation and Collective Bargaining Power

Ionis Pharmaceuticals issues 0% collective agreements. Target value per method: min. 80%

CEO Pay Ratio

CEO Brett P. Monia earns 44 times the median salary of employees. Target value per method: max. 30 times

Employee Turnover Rate

Ionis Pharmaceuticals has an employee turnover rate of 6,6%. Target value per method: max. 10%

Harassment and Discrimination at the Workplace

Ionis Pharmaceuticals meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria

Gender

49%

Women on Board

Ionis Pharmaceuticals has 25% women across its top leadership and supervisory bodies. Target value per method: min. 40%

Gender Pay Gap

No data available for Ionis Pharmaceuticals. Target value per method: max. 3%

Women in Management

Ionis Pharmaceuticals employs 29% female managers. Target value per method: min. 40%

Glass Ceiling

The proportion of women in senior management at Ionis Pharmaceuticals is 51,8% of the proportion of women in the overall workforce. Target value per method: min. 90%

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

Renewable Energy

Greenhouse Gas Emissions

Supply Chain

Waste Recycling

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

Compare Ionis Pharmaceuticals with ...

Ionis Pharmaceuticals

?

Impact Score

Climate

Society

Gender

40%

67%

49%

Ionis Pharmaceuticals

?

Impact Score

Climate

Society

Gender

Sources of sustainability performance

Metric	Value	Unit	Year	PDF Name	PDF Page
CEO Pay Ratio
CEO name	Brett P. Monia		2025	sec-def-14a-2025-remuneration-report.pdf	70
CEO-to-median-salary-ratio	44	Ratio	2025	sec-def-14a-2025-remuneration-report.pdf	132
Employee Turnover Rate
Employee turnover	6,6	%	2025	2025-Corporate-Responsiblity-Report.pdf	39
Glass Ceiling
Women in workforce	56	%	2025	2025-Corporate-Responsiblity-Report.pdf	35
Women in management	29	%	2025	2025-Corporate-Responsiblity-Report.pdf	35
Greenhouse Gas Emissions
Number of employees	1 243	people	2025	2025-Corporate-Responsiblity-Report.pdf	35
Scope 1 emissions	2 615	Metric tons CO2e	2025	2025-Corporate-Responsiblity-Report.pdf	36
Scope 2 emissions, market based	3 133	Metric tons CO2e	2025	2025-Corporate-Responsiblity-Report.pdf	36
Harassment and Discrimination at the Workplace
Confidentiality mechanisms	Yes		2025	2025-Corporate-Responsiblity-Report.pdf	32
Incident notification mechanism	Yes		2025	2025-Corporate-Responsiblity-Report.pdf	32
Anti-discrimination policy	Yes		2025	sec-10-k-2025-annual-report.pdf	40
Retaliation safeguards	Yes		2025	Code of Ethics and Business Conduct_Approved June 5 2024.pdf	9
Renewable Energy
Total energy consumption	12 339	MWh	2025	2025-Corporate-Responsiblity-Report.pdf	36
Total renewable energy consumption	5 621	MWh	2025	2025-Corporate-Responsiblity-Report.pdf	36
Union Formation and Collective Bargaining Power
Collective bargaining agreements coverage	0	%	2025	sec-10-k-2025-annual-report.pdf	39
Recycling and Recovery of Waste
Total waste generation	587	Tons	2025	2025-Corporate-Responsiblity-Report.pdf	36
Waste recycled	68	Tons	2025	2025-Corporate-Responsiblity-Report.pdf	36
Women on Board
Women on executive board	1	people	2025	sec-def-14a-2025-remuneration-report.pdf	70
Executive board size	6	people	2025	sec-def-14a-2025-remuneration-report.pdf	70
Women on supervisory board	3	people	2025	2025-Corporate-Responsiblity-Report.pdf	36
Supervisory board size	10	people	2025	2025-Corporate-Responsiblity-Report.pdf	36
Women in Management
Women in management	29	%	2025	2025-Corporate-Responsiblity-Report.pdf	35

Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

Find more sustainable companies

Home Find Companies & ETFs Learn to invest Academy Glossary Our Method

Imprint Privacy Policy GTC FAQContact Us

© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev